Siemens expands preclinical alliance

Article

The scope of a marketing agreement that allows Siemens Medical Solutions to market Gamma Medica's molecular imaging animal scanner has been expanded to cover worldwide markets. The two companies began their alliance last July when Siemens obtained U.S.

The scope of a marketing agreement that allows Siemens Medical Solutions to market Gamma Medica's molecular imaging animal scanner has been expanded to cover worldwide markets. The two companies began their alliance last July when Siemens obtained U.S. marketing rights for the scanner. The expanded agreement covers X-SPECT, Gamma Medica's second-generation MicroSPECT system. This dual-modality system for preclinical imaging combines SPECT with CT. Designed for in vivo imaging of small animals, it is used primarily in the study of disease processes and for drug development.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.